Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S64315 in AML or MDS
NCT02979366Phase 1Completed
- Sponsor
- Servier
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of S64315 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Servier. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events and 3 more. Started Mar 2017; status: completed.
02
Drugs
S64315
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02979366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979366.